Future Market Insights, a leading player in the pharmaceutical industry, anticipates substantial growth in the global drug-induced dyskinesia industry based on recent industry trends and market analysis. The global drug-induced dyskinesia industry, valued at US$ 382 Million in 2022, is expected to reach US$ 399.8 Million by 2023, showcasing a promising trajectory. Further projections indicate a steady Compound Annual Growth Rate (CAGR) of 4.25% from 2023 to 2033, ultimately reaching a valuation of US$ 620.2 Million by the end of 2033.
The growth of the global drug-induced dyskinesia industry can be attributed to several factors. A surge in demand is driven by the escalating prevalence of drug-induced dyskinesia, primarily associated with an increased incidence of neurologic disorders such as schizophrenia, bipolar disorder, and Alzheimer’s disease. Future Market Insights recognizes the pressing need for advanced therapies to address these disorders, prompting substantial R&D efforts and a robust product pipeline.
Request A Report Sample To Gain Comprehensive Insights! https://www.futuremarketinsights.com/reports/sample/rep-gb-16150
In addition to the rising prevalence of neurologic disorders, increasing consumer awareness, a desire for more potent therapies, and technological advancements have contributed significantly to the expansion of the drug-induced dyskinesia market. The industry’s growth is further fueled by innovations in treatment methodologies, creating a conducive environment for the development and introduction of novel and effective therapeutic solutions.
Future Market Insights is committed to playing a pivotal role in meeting the evolving demands of the global drug-induced dyskinesia market. With a focus on innovation, quality, and patient-centric solutions, Future Market Insights aims to contribute to the advancement of therapeutic options for individuals affected by neurologic disorders.
As we navigate through the projected period of 2023-2033, Future Market Insights remains dedicated to its mission of improving global health outcomes. The anticipated growth in the drug-induced dyskinesia market aligns with our commitment to innovation and underscores the importance of addressing the unmet needs of patients worldwide.
Key Takeaways from the Market Study:
- The global drug-induced dyskinesia industry is currently worth more than US$ 382 Million.
- In 2023, the VMAT 2 segment by drug class is expected to take the dominant market share of 46%.
- In 2023, considering the end-user type, the hospitals segment is predicted to gain a 32% market share.
- The North American market for drug-induced dyskinesia is predicted to grow with a steady CAGR of 4.3% from 2023-2033.
- The APAC for drug-induced dyskinesia is expected to grow with a steady CAGR of 3.5% during 2023-2033.
“During the next ten years, the market for drug-induced dyskinesia will grow robustly owing to increasing neuroleptic patients and rising elderly population.” comments a Future Market Insights analyst.
Get In Touch With Our Analyst To Resolve Any Doubts You May Have! https://www.futuremarketinsights.com/ask-question/rep-gb-16150
Competitive Landscape:
- Teva Pharmaceuticals
- Neurocrine Bioscience
- Sun Pharmaceutical Industries Ltd
- SteriMax Inc.
- Lannett Co Inc
- Adamas Pharmaceuticals, Inc
- Sanis
- AbbVie Inc.
- Dystonia Medical Research Foundation
- Pharos: Illuminating the Druggable Genome
Some Notable Advancements In The Global Market For Drug-Induced Dyskinesia Are:
At the American Mental Association Annual Meeting in May 2022, Neurocrine Biosciences presented different INGREZZA (valbenazine) findings on drug-induced dyskinesia improvements and stabilization of psychiatric symptoms.
The study discovered that long-term (48-week) care with once-daily INGREZZA (40 mg or 80 mg) led to significant clinician-rated as well as self-rated global advancements of drug-induced dyskinesia symptoms while maintaining psychiatric symptom consistency, regardless of the patient’s primary psychological condition.
In March 2022, Neurocrine Bioscience and Mitsubishi Tanabe Pharma Corporation shared the news that DYSVAL (Valbenazine), a medication used to treat drug-induced dyskinesia, has been given regulatory clearance in Japan.
According to their agreement, Neurocrine Biosciences will be entitled to royalty payments at scaled percentages on MTPC’s prospective net sales of valbenazine in Japan as well as other specified Asian markets. Mitsubishi Tanabe Pharma Corporation will be liable for all costs associated with the development, manufacturing, and commercialization of valbenazine.
Revolutionizing Customer Engagement: Learn from Our Customization Report! https://www.futuremarketinsights.com/customization-available/rep-gb-16150
Key Segments Covered In The Drug-induced dyskinesia industry Report:
Drug-induced dyskinesia industry By Drug Class:
- Dopamine-Depleting Medications
- Vmat2 Inhibitors
- Gaba Receptor Agonist Medications
- Anticholinergic Medications
Drug-induced dyskinesia industry By End User:
- Hospitals
- Clinics
- Others
Unlock Exclusive Market Segments Insights: Buy Now! https://www.futuremarketinsights.com/checkout/16150
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube